| Recruiting | Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects NCT07421739 | Aura Biosciences | — |
| Recruiting | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive L NCT06940739 | Iovance Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma NCT06717126 | iOnctura | Phase 2 |
| Recruiting | Resistance Exercise in Patients With Ocular Melanoma NCT06970236 | University of Valencia | N/A |
| Active Not Recruiting | Eye Plaque Brachytherapy for Ocular Melanoma NCT06432660 | Duke University | — |
| Recruiting | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-0 NCT06007690 | Aura Biosciences | Phase 3 |
| Completed | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma NCT05628883 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma NCT05524935 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma NCT05187884 | St Vincent's Hospital, Sydney | Phase 2 |
| Withdrawn | Definity for Ultrasound of Intraocular Tumors NCT01930968 | Emory University | — |
| Completed | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With M NCT04364230 | Craig L Slingluff, Jr | Phase 1 / Phase 2 |
| Completed | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With P NCT04417530 | Aura Biosciences | Phase 2 |
| Completed | iSITE: Investigation of Somatic Alterations in Tumours of the Eye NCT06861647 | The Wellcome Sanger Institute | — |
| Unknown | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma NCT03528408 | Suthee Rapisuwon | Phase 2 |
| Completed | Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton The NCT03172299 | Centre Hospitalier Universitaire de Nice | Phase 3 |
| Completed | Study in Subjects With Small Primary Choroidal Melanoma NCT03052127 | Aura Biosciences | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases NCT02858869 | Emory University | Phase 1 |
| Unknown | The Role of Inflammation in Ocular Tumours NCT02909517 | Unity Health Toronto | — |
| Completed | Neoadjuvant and Adjuvant Checkpoint Blockade NCT02519322 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV NCT02129075 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma NCT01893099 | Centre Hospitalier Universitaire Vaudois | Phase 1 |
| Completed | THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease NCT01355120 | Prof. Dr. med. Dirk Schadendorf | Phase 2 |
| Completed | STA-9090(Ganetespib) in Metastatic Ocular Melanoma NCT01200238 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye NCT00621439 | Emory University | N/A |
| Completed | Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone NCT00351728 | Jonsson Comprehensive Cancer Center | — |
| Terminated | Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and NCT00346372 | Jonsson Comprehensive Cancer Center | — |
| Unknown | Study of Metastatic Ocular Melanoma NCT00168870 | Charite University, Berlin, Germany | Phase 2 |
| No Longer Available | Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets NCT01728051 | Delcath Systems Inc. | — |